Fundamental Analysis of LIXTE BIOTECHNOLOGY HOLDINGS(NASDAQ:LIXT) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to LIXT. LIXT was compared to 561 industry peers in the Biotechnology industry. While LIXT seems to be doing ok healthwise, there are quite some concerns on its profitability. LIXT does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year LIXT has reported negative net income.

LIXT had a negative operating cash flow in the past year.

In the past 5 years LIXT always reported negative net income.

In the past 5 years LIXT always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of LIXT (-235.90%) is worse than 92.07% of its industry peers.

LIXT has a worse Return On Equity (-292.66%) than 73.87% of its industry peers.

		Industry Rank	Sector Rank
ROA	-235.9%
ROE	-292.66%
ROIC	N/A

ROA(3y)-121.26%

ROA(5y)-103.5%

ROE(3y)-129.96%

ROE(5y)-111.07%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LIXT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LIXT has more shares outstanding than it did 1 year ago.

LIXT has more shares outstanding than it did 5 years ago.

There is no outstanding debt for LIXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

LIXT has an Altman-Z score of -39.70. This is a bad value and indicates that LIXT is not financially healthy and even has some risk of bankruptcy.

LIXT has a worse Altman-Z score (-39.70) than 92.97% of its industry peers.

There is no outstanding debt for LIXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-39.7

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 5.13 indicates that LIXT has no problem at all paying its short term obligations.

The Current ratio of LIXT (5.13) is comparable to the rest of the industry.

A Quick Ratio of 5.13 indicates that LIXT has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 5.13, LIXT is in line with its industry, outperforming 55.86% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	5.13
Quick Ratio	5.13

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.98% over the past year.

EPS 1Y (TTM)45.98%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%10.72%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LIXT. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LIXT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LIXTE BIOTECHNOLOGY HOLDINGS

NASDAQ:LIXT (1/6/2025, 5:20:02 PM)

After market: 2.32 -0.08 (-3.33%)

2.4

+0.07 (+3%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-08 2024-11-08/bmo

Earnings (Next)03-17 2025-03-17

Inst Owners8.6%

Inst Owner Change0%

Ins Owners10.03%

Ins Owner Change0%

Market Cap5.40M

Analysts0

Price TargetN/A

Short Float %6.59%

Short Ratio0.16

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	3.95
P/tB	3.95
EV/EBITDA	N/A

EPS(TTM)-1.78

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-1.54

FCFYN/A

OCF(TTM)-1.54

OCFYN/A

SpS0

BVpS0.61

TBVpS0.61

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-235.9%
ROE	-292.66%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-121.26%

ROA(5y)-103.5%

ROE(3y)-129.96%

ROE(5y)-111.07%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.13
Quick Ratio	5.13
Altman-Z	-39.7

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)45.98%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%10.72%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y30.01%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y23.61%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y23.61%

OCF growth 3YN/A

OCF growth 5YN/A

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens